Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Febuxostat for Endothelial Dysfunction in Hemodialysis Patients
NCT02866214Phase 3Completed
- Sponsor
- Ain Shams University
- Start
- Aug 2016
- Primary completion
- Oct 2016
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of febuxostat in endothelial dysfunction and hyperuricemia, sponsored by Ain Shams University. Primary endpoint: Asymmetric Dimethylarginine at 2 months. Started Aug 2016; status: completed.
02
Drugs
febuxostat
03
Conditions
endothelial dysfunctionhyperuricemia
Beyond the preview
Go deeper on NCT02866214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02866214.